Abstract: TH-PO139

Can THSD7A Be a New Marker for Diagnosing Idiopathic Membranous Nephropathy? A Systematic Review and Meta-Analysis of the Diagnostic Value of THSD7A in IMN

Session Information

Category: Glomerular

  • 1005 Clinical Glomerular Disorders

Authors

  • Ren, Song, Renal Department and Institute of Nephrology, Sichuan Provincial People?s Hospital, Chengdu, China
  • Wu, Changwei, Renal Department and Institute of Nephrology, Sichuan Provincial People?s Hospital, Chengdu, China
  • Li, Guisen, Renal Division and Institute of Nephrology, Sichuan Academy of Medical Sciences and Sichuan Provincial People?s Hospital, Chengdu, China
  • Wang, Li, Renal Division and Institute of Nephrology, Sichuan Academy of Medical Sciences and Sichuan Provincial People?s Hospital, Chengdu, China
  • Hong, Daqing, Sichuan Provincial People's Hospital, CHENGDU, China
Background

Thrombospondin type 1 domain–containing 7A (THSD7A) is a new target antigen in patients with idiopathic membranous nephropathy. Moreover, malignancies are also found in THSD7A-positive membranous nephropathy patients. We aimed to systematically evaluate prevalence of THSD7A in the IMN patients and malignancies in THSD7A-postive patients.

Methods

We searched English database including MEDLINE, Embase,Cochrane Library and Chinese database including CNKI, VIP and Wanfang database to Jan 4, 2017 with the term “THSD7A” or “thrombospondin type 1 domain-containing 7A”. Meta analysis was used to explore the positive rate of THSD7A in the patients with idiopathic membranous nephropathy. Subgroup analysis was done according to the race, sample size, and detecting method of THSD7A. The incidence of malignancies in THSD7A positive patients was also summarized.

Results

Ten studies involving 3061 participants were eventually included in this review. The prevalence of THSD7A was 3% (95% CI, 3%–4%). In the anti-phospholipase A2 receptor (PLA2R)-negative patients, the prevalence of THSD7A was 10% (95% CI, 6%–15%). A total of 77 patients were detected for positive circulating antibodies, and the prevalence of THSD7A was lower at 3% (95% CI, 2%–4%). Overall 72 patients were THSD7Apositive detected by renal biopsy with immunohistochemistry, and the prevalence was 3% (95% CI 3%-4%). Subgroup analysis did not show significant differences in the prevalence of THSD7Abetween races and study sample sizes.Among THSD7A-postive patients, 2/10 studies reported malignancies with the incidence varied from 20% to 25%.

Conclusion

The prevalence of THSD7A is not uncommon in the patients with IMN, but more common in the PLA2R-negtive patients. Malignancies should be screened and closely monitored in THSD7A-positvie membranous nephropathy patients.